DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

A South Bay biotech firm has bought a big San Jose office and research building in a deal that could enable the life sciences firm to expand its local operations considerably. Vibrant Wellness has ...

Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks ...

2024年9月13日，是生物科技股首次公开募股（IPO）异常繁忙的一天，纳斯达克同时迎来了Bicara Therapeutics、Zenas BioPharma和MBX Biosciences三家公司的上市，共筹集了7亿多美元。

Bob Duggan, 80, has gone from baking cookies to building robots, investing in biotech companies, and ranking among the ...

Scotiabank analyst George Farmer maintained a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of ...

Anima Biotech , the Tech.Bio leader in Visual Biology for drug discovery, will showcase its Lightning AI platform at the 3rd annual AI/ML-Enabled Drug Discovery Session,“Leveraging GenAI to Improve ...

Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

周一，Piper Sandler基于CARTITUDE-4 III期研究数据的公布，维持对Legend Biotech Corp.（纳斯达克股票代码：LEGN）的增持评级和90.00美元的目标价。该研究结果在国际骨髓瘤学会会议上公布，显示由Legend Biotech开发的CARVYKTI治疗方案与PVd/DPd治疗相比，将复发或难治性多发性骨髓瘤（r/rMM）患者的死亡风险降低了45%。

专注于生物制品的生物技术公司NKGen Biotech, Inc.面临着可能从纳斯达克全球市场摘牌的风险，原因是其股价未能达到最低投标价格要求。2024年9月23日，该公司收到纳斯达克的通知，称其普通股连续30个交易日的收盘价低于每股1.00美元的要求。 根据纳斯达克的规则，NKGen Biotech有180天的时间，即到2025年3月24日，来重新达到合规要求。如果公司股价连续至少10个交易日收 ...